Current concepts and advances in graft-versus-host disease immunology
Worldwide, each year over 30,000 patients undergo an allogeneic hema-topoietic stem cell
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …
CD28/B7 system of T cell costimulation
DJ Lenschow, TL Walunas… - Annual review of …, 1996 - annualreviews.org
▪ Abstract T cells play a central role in the initiation and regulation of the immune response to
antigen. Both the engagement of the TCR with MHC/Ag and a second signal are needed for …
antigen. Both the engagement of the TCR with MHC/Ag and a second signal are needed for …
Graft-versus-host disease
WD Shlomchik - Nature Reviews Immunology, 2007 - nature.com
Allogeneic haematopoietic stem-cell transplantation (SCT) is a curative therapy for
haematological malignancies and inherited disorders of blood cells, such as sickle-cell …
haematological malignancies and inherited disorders of blood cells, such as sickle-cell …
Immunobiology of allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved into an effective
adoptive cellular immunotherapy for the treatment of a number of cancers. The …
adoptive cellular immunotherapy for the treatment of a number of cancers. The …
The immunologic basis for the treatment of psoriasis with new biologic agents
JG Krueger - Journal of the American Academy of Dermatology, 2002 - Elsevier
Psoriasis vulgaris is the most prevalent T-cell-mediated inflammatory disease in humans.
The pathogenesis of psoriasis is linked to activation of several types of leukocytes that …
The pathogenesis of psoriasis is linked to activation of several types of leukocytes that …
Cytokines and costimulation in acute graft-versus-host disease
GR Hill, M Koyama - Blood, The Journal of the American …, 2020 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (alloSCT) is an important curative
therapy for high-risk hematological malignancies, but the development of severe and/or …
therapy for high-risk hematological malignancies, but the development of severe and/or …
GVHD prophylaxis 2020
M Gooptu, JH Antin - Frontiers in immunology, 2021 - frontiersin.org
Graft-vs. host disease (GVHD), both acute and chronic are among the chief non-relapse
complications of allogeneic transplantation which still cause substantial morbidity and …
complications of allogeneic transplantation which still cause substantial morbidity and …
Current and emerging strategies for the prevention of graft-versus-host disease
SW Choi, P Reddy - Nature reviews Clinical oncology, 2014 - nature.com
Graft-versus-host disease (GVHD) represents the most serious and challenging
complication of allogeneic haematopoietic stem-cell transplantation (HSCT). New insights …
complication of allogeneic haematopoietic stem-cell transplantation (HSCT). New insights …
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
VT Ho, RJ Soiffer - Blood, The Journal of the American Society …, 2001 - ashpublications.org
Despite significant progress in the past 20 years, graft-versus-host disease (GVHD) remains
a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell …
a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell …
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT
K Rezvani, S Mielke, M Ahmadzadeh, Y Kilical… - Blood, 2006 - ashpublications.org
Regulatory T cells (Tregs) that constitutively express FOXP3 are instrumental to the
maintenance of tolerance and may suppress graft-versus-host disease (GVHD) in humans …
maintenance of tolerance and may suppress graft-versus-host disease (GVHD) in humans …